Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
Autor: | Mohammed AF; School of Pharmacy & Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 3NB, UK; Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Assiut University, Assiut, Egypt., Andrei G; Rega Institute for Medical Research, KU Leuven, Herestraat 49 Box 1030, Leuven 3000, Belgium., Hayallah AM; Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Assiut University, Assiut, Egypt., Abdel-Moty SG; Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Assiut University, Assiut, Egypt., Snoeck R; Rega Institute for Medical Research, KU Leuven, Herestraat 49 Box 1030, Leuven 3000, Belgium., Simons C; School of Pharmacy & Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 3NB, UK. Electronic address: simonsc@cardiff.ac.uk. |
---|---|
Jazyk: | angličtina |
Zdroj: | Bioorganic & medicinal chemistry [Bioorg Med Chem] 2019 Mar 15; Vol. 27 (6), pp. 1023-1033. Date of Electronic Publication: 2019 Feb 02. |
DOI: | 10.1016/j.bmc.2019.02.005 |
Abstrakt: | A series of tricyclic penciclovir (PCV) and hydroxybutylguanine (HBG) derivatives have been prepared with enhanced lipophilicity following an efficient synthetic route. All the novel tricyclic derivatives were evaluated for inhibitory activity against herpes simplex virus 1 and 2 (HSV-1, HSV-2) and thymidine kinase deficient (ACV resistant) HSV-1. The tricyclic HBG derivatives were devoid of inhibitory activity however several of the tricyclic PCV derivatives showed promising antiviral activity, in particular 9g (R = 4-MeO-C (Copyright © 2019 Elsevier Ltd. All rights reserved.) |
Databáze: | MEDLINE |
Externí odkaz: |